Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Global Volume of IVD Procedures Exceeds 21 Billion in 2016

By LabMedica International staff writers
Posted on 18 Apr 2017
The global volume of in vitro diagnostic (IVD) procedures, excluding the over-the counter (OTC) point of care (POC) market and professional POC glucose monitoring activity, reached 21.4 billion in 2016. More...
Currently, an estimated 80% of all conditions diagnosed by physicians worldwide are based at least partially on the results of IVD procedures.

These are the latest findings of Kalorama Information, an independent medical market research firm.

Over the past few years, significant progress has been made in IVD testing technology due to advances in functional genomics and proteomics, coupled with innovations in automated instruments, bioinformatics, and telecommunications. As a result of developments in IVD testing technology, new tools are becoming available for the detection and analysis of major health problems across the world, such as cancer, diabetes, heart disorders, and infectious diseases.

Evolving global epidemiological patterns, coupled with changing patient care approaches, are driving demand for a full range of routine and esoteric IVD procedures. Medical providers select IVD procedures based on various factors such as nature of the healthcare activity involved, presence or absence of obvious patient symptoms, patient characteristics and history, and, increasingly, cost and third-party reimbursement eligibility. Based on broad detection capabilities, core laboratories – which consolidate routine tests from multiple disciplines, chemistry, immunoassay, urinalysis, microbiology, coagulation, HPV cytology – held the largest share of global IVD procedure volume in 2016.

Going forward, medical providers across the world are expected to depend increasingly on POC and clinical laboratory tests to identify patient health problems in early stages and prescribe appropriate therapies. Increasing applications in testing of hospital patients, patients undergoing physical examinations and periodic healthcare checkups, and patients suspected of ingesting toxic substances will drive the volume of core laboratory procedures implemented across the world. An aging population and rising level of diseases and disorders worldwide will continue to drive the volume of patient testing conducted in most countries. Moreover, the adaptation of molecular and other advanced life science technologies to new and improved reagents and instruments will broaden IVD capabilities in detecting medical conditions. However, with several countries witnessing shorter hospital stays and tighter health insurance restrictions on outpatient testing, the growth in the volume of core laboratory procedures will slow down from the historical levels. Additionally, the need for some core laboratory tests will be eliminated by increasing competition from POC, molecular, and histology/cytology diagnostics.

There are about 500 participants in the IVD industry, including small, narrowly focused firms as well as large diversified multinational companies. The competitive structure of the global IVD industry is relatively concentrated at the top tier, with 10 large, multinational corporations controlling almost 70% of the global market in 2016. These industry leaders compete in multiple product segments and have established their strong competitive positions by combining internal research and development (R&D) activities with acquisitions and external collaborative agreements. Since IVD products serve healthcare applications, producers are subject to strict government regulations and serve highly price-sensitive markets. In order to achieve success in the industry, producers will be required to effectively balance R&D, productivity, manufacturing efficiencies, effective marketing and distribution, and responsive customer service.


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.